Prime Medicine (NASDAQ:PRME) Stock Price Down 6.5% – What’s Next?

Posted by Geri Gentry on Jul 15th, 2026

Prime Medicine, Inc. (NASDAQ:PRME – Get Free Report)’s share price traded down 6.5% during trading on Monday . The stock traded as low as $3.54 and last traded at $3.5350. Approximately 923,638 shares traded hands during trading, a decline of 68% from the average daily volume of 2,931,771 shares. The stock had previously closed at $3.78.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on PRME shares. HC Wainwright raised Prime Medicine from a “neutral” rating to a “buy” rating and set a $8.00 target price for the company in a research note on Monday, June 29th. Weiss Ratings reissued a “sell (e+)” rating on shares of Prime Medicine in a research note on Wednesday, June 3rd. The Goldman Sachs Group set a $6.00 price target on Prime Medicine in a report on Monday, June 22nd. TD Cowen reaffirmed a “buy” rating on shares of Prime Medicine in a research report on Wednesday, July 8th. Finally, Wall Street Zen downgraded shares of Prime Medicine from a “sell” rating to a “strong sell” rating in a research report on Wednesday, May 13th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $7.53.

Read Our Latest Analysis on PRME

Prime Medicine Stock Performance

The company has a market capitalization of $626.75 million, a price-to-earnings ratio of -2.82 and a beta of 2.26. The company has a 50 day moving average price of $3.30 and a 200 day moving average price of $3.58.

Prime Medicine (NASDAQ:PRME – Get Free Report) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.04). The firm had revenue of $0.86 million for the quarter. Prime Medicine had a negative return on equity of 188.82% and a negative net margin of 4,917.55%. Research analysts forecast that Prime Medicine, Inc. will post -0.98 EPS for the current year.

Institutional Trading of Prime Medicine

Several hedge funds have recently bought and sold shares of the business. State Street Corp raised its holdings in Prime Medicine by 293.0% during the fourth quarter. State Street Corp now owns 5,095,510 shares of the company’s stock worth $17,681,000 after buying an additional 3,798,884 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Prime Medicine by 35.7% during the third quarter. Vanguard Group Inc. now owns 4,921,865 shares of the company’s stock valued at $27,267,000 after buying an additional 1,294,355 shares during the last quarter. Balyasny Asset Management L.P. grew its holdings in shares of Prime Medicine by 6,426.4% during the fourth quarter. Balyasny Asset Management L.P. now owns 3,124,362 shares of the company’s stock valued at $10,842,000 after buying an additional 3,076,489 shares during the last quarter. Woodline Partners LP bought a new stake in shares of Prime Medicine during the third quarter worth about $16,634,000. Finally, RA Capital Management L.P. bought a new stake in shares of Prime Medicine during the third quarter worth about $16,620,000. Institutional investors and hedge funds own 70.37% of the company’s stock.

Prime Medicine Company Profile

(Get Free Report)

We are a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, Prime Editors, to address the widest spectrum of diseases by deploying our Prime Editing technology, which we believe is a versatile, precise, efficient and broad gene editing technology. Genetic mutations implicated in disease are diverse and can range from errors of a single base, known as point mutations, to errors that extend beyond a single base, such as insertions, deletions, duplications, or combinations thereof.